Discovery of novel Henipavirus inhibitors

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: Thomas William Geisbert
Organization: UNIVERSITY OF TEXAS MED BR GALVESTON
Fiscal Year: 2023
Award: $2,317,735
Funding agency: National Institute of Allergy and Infectious Diseases

PROJECT 3 – ABSTRACT
The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory
pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for
henipaviruses for pandemic preparedness. We will achieve the goal by pursuing three aims. (i) Screen and
identify novel compounds for Nipah and/or Hendra virus inhibition. Since Nipah and Hendra viruses should be
handled at BSL4, it is challenging to perform high-throughput screen at high containment. To overcome this
bottleneck, we will use a BSL2 Cedar henipavirus as a surrogate system for antiviral screen. Hits identified from
the Cedar henipavirus assay will be validated in Hendra and Nipah viruses at the BSL4 facility. (ii) Develop tool
compounds, determine target protein, and optimize molecules. (iii) Evaluate lead compounds in relevant in vitro
and in vivo models and select Development Candidate for IND-enabling studies. The proposed cell-based
approach may discover novel antiviral targets that may not be tractable for target-based antiviral approach.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><African Green Monkey><Animals><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Assay><Automation><BSL-4 facility><BSL4 facility><Bangladesh><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biology><Brain Inflammation><Breakbone Fever Virus><COVID-19 virus><COVID19 virus><Case Fatality Rates><Cell Body><Cells><Chemicals><Chlorocebus aethiops><Chlorocebus sabaeus><CoV-2><CoV2><Communicable Diseases><Containment><Coronaviridae><Coronavirus><Country><Cricetinae><DENV><Dengue><Dengue Virus><Dengue fever virus><Development><Disease><Disease Outbreaks><Disorder><Drug Design><Drug Targeting><Drug resistance><Drug resistant viral><Encephalitis><Equine Morbillivirus><Evaluation><Exclusion><Family><Federation of Malaya><Flavivirus><Generations><Genetic Alteration><Genetic Change><Genetic defect><Goals><Green Monkey><Group B Arbovirus><Hamsters><Hamsters Mammals><Hendra><Hendra Virus><Henipavirus><High Throughput Assay><Human><In Vitro><India><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Lead><Luciferase Immunologic><Luciferases><Lytotoxicity><Malay Federation><Malaya><Malaysia><Maps><Medical><Medicinal Chemistry><Miniaturisations><Miniaturization><Modeling><Modern Man><Modernization><Mutation><Nipah Virus><Outbreaks><PK/PD><Paramyxoviridae><Paramyxovirus><Pathogenicity><Pb element><Persons><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Phenotype><Philipines><Philippines><Phillipines><Phillippines><Proteins><Recombinants><Research><Rodent><Rodentia><Rodents Mammals><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Structure><Structure-Activity Relationship><System><Technology><Testing><Texas><Therapeutic><Transmission><Triage><Universities><Vaccines><Variant><Variation><Viral><Viral Genes><Virus><Wuhan coronavirus><animal efficacy><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapy><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><biophysical approaches><biophysical methodology><biophysical methods><biophysical techniques><biosafety level 4 facility><chemical structure function><clinical candidate><combat><corona virus><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytotoxicity><developmental><drug discovery><drug resistant><drug resistant virus><efficacy study><entire genome><full genome><genome mutation><hCoV19><heavy metal Pb><heavy metal lead><high throughput screening><human pathogen><in vivo><in vivo Model><inhibitor><lead optimization><man><member><nCoV2><novel><pandemic concern><pandemic disease preparedness><pandemic planning><pandemic potential><pandemic preparedness><pandemic readiness><pandemic risk><pandemic threat><pharmacokinetics and pharmacodynamics><pre-clinical><pre-clinical development><preclinical><preclinical development><protective efficacy><resistance to Drug><resistant to Drug><respiratory><respiratory pathogen><reverse genetics><safety study><screening><screenings><small molecule><structure function relationship><tool><transmission process><viral infectious disease treatment><virology><whole genome>